Key Takeaways AVNS announced a co-marketing deal to integrate radiofrequency ablation with imaging for outpatient pain care.Siemens Healthineers combines mobile C-arm imaging with RFA to improve precision and workflow efficiency.AVNS targets ambulatory centers as pain procedures increasingly shift from hospitals to outpatient settings.Avanos Medical (AVNS) and Siemens Healthineers recently announced a strategic co-marketing agreement aimed at advancing outpatient and interventional pain management by integr ...

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: Hidden Gems: 10 Small-Caps Worth Watching. We came across a bullish thesis on Avanos Medical, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on AVNS. Avanos Medical, Inc.'s share was trading at $11.97 as of January 12th. AVNS’s trailing P/E was 164.60 according to Yahoo Finance. 10 Best Small-Cap Biotech Stocks Un ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Avanos Medical aims to enhance patient quality of life through a focused long-term strategy that emphasizes durable growth and value creation [2]. Group 1: Company Strategy - The company is experiencing solid mid-single-digit growth and holds market-leading positions with established reimbursement [4]. - Avanos is expanding its global direct sales organization and has a newly appointed management team, which includes several new leaders [4]. - The company has an attractive M&A pipeline that presents growth opportunities and maintains a strong balance sheet to support capital deployment [4].

Avanos Medical (NYSE:AVNS) FY Conference January 13, 2026 05:15 PM ET Company ParticipantsDave Pacitti - CEOJalanjith Timmy - AssociateJalanjith TimmyGood afternoon, everyone, and thank you for joining us this week at the J.P. Morgan Healthcare Conference. Great to have you all this afternoon join us. My name is Jalankith Timmy, and I'm an associate on the JPMorgan Healthcare team. Today, it is my pleasure to introduce Avanos Medical. Joining us for today's presentation is Dave Pacitti, CEO of Avanos, and S ...

These statements are subject to risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements, including risks related to changes in the competitive environment; market demand and pricing pressure; cost containment measures that could adversely affect the price of or demand for our products; raw material, energy, and other input costs; supply chain disruptions (including availability of drugs used in our Surgical Pain and Recovery product ...

Company Overview - Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions to help patients return to their daily activities [2] - The company is headquartered in Alpharetta, Georgia, and is committed to addressing significant healthcare needs, including providing nutrition support for patients transitioning from hospital to home and reducing opioid use during recovery [2] - Avanos develops, manufactures, and markets recognized brands globally, holding leading market positions across multiple categories in its portfolio [2] Upcoming Event - Dave Pacitti, the CEO of Avanos Medical, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13 at approximately 2:15 p.m. PST [1] - A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived for future access [1]

Core Viewpoint - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List, indicating a negative outlook for these companies based on recent earnings estimate revisions [1][2]. Company Summaries - **Avanos Medical, Inc. (AVNS)**: This medical technology company has seen its current year earnings estimate revised downward by 3.3% over the last 60 days [1]. - **Archer-Daniels-Midland Company (ADM)**: An agricultural commodities and ingredients company, ADM's current year earnings estimate has been revised downward by 8.6% over the last 60 days [1]. - **Bank OZK (OZK)**: This company provides retail and commercial banking services, with its current year earnings estimate revised downward by 3.4% over the last 60 days [2].

Core Viewpoint - Avanos Medical reported a mixed performance in its Q3 2025 earnings, with adjusted EPS beating estimates but showing a significant year-over-year decline, while revenues increased modestly, driven by growth in its Specialty Nutrition Systems and Pain Management segments [2][3][14]. Financial Performance - Adjusted EPS for Q3 2025 was 22 cents, down 38.9% year over year, but exceeded the Zacks Consensus Estimate of 16 cents by 37.5% [2] - Revenues reached $177.8 million, reflecting a 4.3% increase year over year and surpassing the Zacks Consensus Estimate by 6.9% [3] - GAAP loss per share was 3 cents compared to an EPS of 12 cents in the prior year [2] Segment Analysis - The Pain Management and Recovery (PM&R) segment generated revenues of $59 million, up 2.1% year over year, slightly above projections [5] - The Specialty Nutrition Systems (SNS) segment reported revenues of $114 million, a 16.1% increase year over year, driven by strong demand in enteral feeding and neonate solutions [7] - The Corporate and Other segment's revenues fell to $4.8 million, down 66.7% year over year, impacted by the divestiture of the Hyaluronic Acid product line [8][9] Margin and Expense Analysis - Adjusted gross profit declined 4.7% year over year to $97.4 million, with adjusted gross margin contracting 390 basis points to 55.7% [11] - Selling and general expenses increased by 3.2% year over year to $83.5 million, while research and development expenses decreased by 7.9% to $5.8 million [11] Financial Position - Cash and cash equivalents at the end of Q3 2025 were $70.5 million, down from $90.3 million at the end of Q2 2025 [13] - Total debt decreased to $102.8 million from $105.1 million in the previous quarter [13] Guidance and Outlook - The company raised its 2025 sales outlook to a range of $690-$700 million, up from $665-$685 million previously [14] - Adjusted EPS guidance for 2025 was increased to between 85 and 95 cents, compared to the previous range of 75 to 95 cents [14] Industry Comparison - Avanos Medical's stock has underperformed, declining 33.1% year-to-date, while the broader S&P 500 has increased by 16.7% [4] - In contrast, TransMedics, a competitor in the same industry, reported a 32.2% year-over-year revenue increase and a significant EPS growth, indicating stronger performance within the sector [18][19]

Core Insights - Avanos Medical, Inc. reported a third-quarter 2025 adjusted EPS of 22 cents, a decline of 38.9% year over year, but exceeded the Zacks Consensus Estimate of 16 cents by 37.5% [1] - Revenues for the quarter reached $177.8 million, reflecting a year-over-year increase of 4.3% and surpassing the Zacks Consensus Estimate by 6.9% [2] - The company raised its 2025 sales guidance to a range of $690-$700 million, up from a previous estimate of $665-$685 million, and increased the lower end of its EPS forecast to between 85 and 95 cents [14] Revenue Breakdown - The Specialty Nutrition Systems (SNS) segment generated revenues of $114 million, up 16.1% year over year, driven by strong demand in enteral feeding and neonatal solutions [8] - The Pain Management and Recovery (PM&R) segment reported revenues of $59 million, a 2.1% increase year over year, with net sales of Radio Frequency Ablation (RFA) products growing 10.5% to $34.6 million [4][5] - The Corporate and Other segment's revenues fell to $4.8 million, down 66.7% year over year, following the divestiture of the Hyaluronic Acid product line [9][10] Margin and Expense Analysis - Adjusted gross profit decreased by 4.7% year over year to $97.4 million, with the adjusted gross margin contracting by 390 basis points to 55.7% [11] - Selling and general expenses rose by 3.2% to $83.5 million, while research and development expenses decreased by 7.9% to $5.8 million [11] - Adjusted operating profit fell 44% to $12.2 million, with the adjusted operating margin contracting by 580 basis points to 6.9% [12] Financial Position - At the end of the third quarter, the company had cash and cash equivalents of $70.5 million, down from $90.3 million at the end of the second quarter, while total debt decreased to $102.8 million [13] - Cumulative net cash provided by operating activities increased to $46.5 million compared to $42.8 million in the prior-year period [13] Strategic Initiatives - The company is focusing on strategic portfolio actions, including divesting non-core assets and acquiring Nexus Medical to enhance its neonatal and pediatric offerings [18] - Cost-transformation initiatives are underway, aimed at achieving significant savings and improving operational efficiency through 2026 [18] - Despite challenges such as tariffs impacting margins, the company is implementing mitigation strategies, including supply-chain relocation and internal cost controls [19]